Extra-osseous Ewing’s Sarcoma Recurrent

Extra-osseous Ewing’s sarcoma recurrent is a rare and aggressive cancer that returns after treatment, presenting significant challenges even with modern therapies and requiring individualized care approaches.

Table of contents

• What Is Extra-osseous Ewing’s Sarcoma
• Understanding Recurrent Disease
• Diagnosis and Testing
• Treatment Approaches
• Prognosis and Challenges

What Is Extra-osseous Ewing’s Sarcoma

Extra-osseous Ewing’s sarcoma is a rare type of cancer that develops in soft tissues rather than in bones. Unlike the more common form of Ewing sarcoma that starts in bones, this type originates from soft tissues such as muscles, tendons, and ligaments that surround and support the bones.^[1]

This cancer is part of a group called the Ewing family of tumors. It is a poorly differentiated, highly malignant round cell tumor that shows aggressive clinical behavior with a high rate of local recurrence and distant spread to other parts of the body.^[1] The condition has also been called extraosseous Ewing sarcoma (meaning Ewing sarcoma in tissue other than bone) and peripheral primitive neuroectodermal tumor.^[5]

extraosseous Ewing sarcoma, peripheral primitive neuroectodermal tumor, EES

Patients with extra-osseous Ewing sarcoma tend to be older on average compared to those with skeletal Ewing sarcoma. The most commonly affected sites include the paravertebral spaces (areas alongside the spine), lower extremities, head and neck, and pelvis.^[1] Rare locations can include the retroperitoneum, omentum, orbit, skin, and chest wall.^[1]

• Paravertebral spaces
• Lower extremities
• Head and neck
• Pelvis
• Chest wall
• Soft tissues (muscles, tendons, ligaments)

Understanding Recurrent Disease

Recurrent Ewing sarcoma means the cancer has come back after initial treatment. This remains an important clinical problem with no standard approach to treatment.^[12] While many patients with newly diagnosed localized Ewing sarcoma can become long-term survivors, relapse continues to be a significant challenge.

Treating patients with recurrent disease is particularly challenging. The 5-year overall survival rate for patients with disseminated or recurrent Ewing sarcoma is less than 30%.^[3] The likelihood of cure remains low, and the gaps in medical knowledge about the best treatment approaches are significant.^[12]

Several factors can affect outcomes in recurrent disease. The location where the cancer returns, the time between initial treatment and recurrence, and the patient’s response to previous treatments all play important roles in determining the prognosis. However, the optimum length of therapy for salvage regimens and use of local control measures remains unknown.^[12]

Diagnosis and Testing

Diagnosing extra-osseous Ewing’s sarcoma and detecting recurrence involves several different types of tests. The available diagnostic tools include ultrasonographic evaluation and computed tomography (CT) or magnetic resonance imaging (MRI), which create detailed pictures of the inside of the body.^[1]

Tissue examination is essential for confirming the diagnosis. This includes histopathologic examination, where tissue samples are studied under a microscope, and immunohistochemical testing, which uses special stains to identify specific proteins in the cancer cells.^[1]

Several histologic and genetic biomarkers have been established to help identify this cancer. A unique genetic change involves the fusion of two genes, called EWSR1 and FLI1, which creates a new abnormal gene that causes cells to multiply uncontrollably.^[3] The genetic material in chromosomes #11 and #22 is mismatched in Ewing sarcoma cells.^[7]

Although these biomarkers are helpful, their utilization needs to be further tested by larger prospective studies to better understand their role in diagnosis and treatment planning.^[1]

Treatment Approaches

Treatment for recurrent extra-osseous Ewing’s sarcoma requires a multimodality approach, meaning it uses several different types of treatment together. However, no comparative studies have been completed to show superiority of any one particular approach for recurrent disease.^[12]

For localized disease, the recommended treatment remains surgery to remove the tumor.^[1] However, chemotherapy, which uses powerful drugs to kill cancer cells, can be added to achieve improved survival. Neoadjuvant chemotherapy (chemotherapy given before surgery) has shown more promising results than adjuvant chemotherapy (chemotherapy given after surgery).^[1]

Various chemotherapy regimens have produced responses in patients with recurrent Ewing sarcoma. Common drug combinations include vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide, often administered according to specific treatment protocols such as the EURO EWING 2012 trial.^[3]

Radiotherapy, which uses high-energy rays to kill cancer cells, is an option to obtain local control of the disease. However, its complications have reduced its utilization in some cases.^[1] In metastatic or recurrent disease, systematic chemotherapy improves survival.^[1]

Optimal treatment protocols for recurrent Ewing sarcoma are lacking, and treatments are individualized based on the patient’s response to treatment and the decisions of tumor boards. Patients with rare tumors such as Ewing sarcoma benefit from multidisciplinary collaboration, resulting in improved quality of care and treatment outcomes.^[3]

Because of the rarity of this cancer and the challenges in treating recurrent disease, enrollment in clinical trials should be strongly encouraged for these patients when feasible.^[12]

Prognosis and Challenges

The prognosis for patients with extra-osseous Ewing’s sarcoma recurrent remains challenging. Patient characteristics and outcomes appear to be different in extra-osseous Ewing sarcoma compared to patients with skeletal Ewing sarcoma, with implications for patient care and prognosis.^[1]

While the prognosis for patients with newly diagnosed localized Ewing sarcoma has been greatly improved by multimodality treatment, treating patients with recurrent disease continues to be difficult.^[3] The 5-year overall survival rate remains below 30% for patients with disseminated or recurrent disease.^[3]

Several prognostic factors have been identified that may help guide patient counseling and therapy decisions. These include the timing of recurrence, the location where the cancer returns, and how well the cancer responds to treatment. However, despite advances in medical care, the likelihood of cure for recurrent disease remains low.^[12]

Because extra-osseous Ewing sarcoma is relatively rare, some pediatric and adult oncologists may be less familiar with the management of relapsed patients. This makes it especially important for patients to receive care at specialized centers with experience in treating this condition and to consider participating in clinical trials when possible.^[12]